BR112015027303A2 - - Google Patents
Info
- Publication number
- BR112015027303A2 BR112015027303A2 BR112015027303A BR112015027303A BR112015027303A2 BR 112015027303 A2 BR112015027303 A2 BR 112015027303A2 BR 112015027303 A BR112015027303 A BR 112015027303A BR 112015027303 A BR112015027303 A BR 112015027303A BR 112015027303 A2 BR112015027303 A2 BR 112015027303A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310174990 | 2013-05-13 | ||
| CN201310174990.6 | 2013-05-13 | ||
| PCT/CN2014/076447 WO2014183555A1 (zh) | 2013-05-13 | 2014-04-29 | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015027303A2 true BR112015027303A2 (pt) | 2017-09-05 |
| BR112015027303B1 BR112015027303B1 (pt) | 2023-04-25 |
Family
ID=51897690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015027303-3A BR112015027303B1 (pt) | 2013-05-13 | 2014-04-29 | Derivado de ácido de cicloalquila, método de preparação do mesmo, e aplicação farmacêutica do mesmo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9637484B2 (pt) |
| EP (1) | EP2998296B1 (pt) |
| JP (1) | JP6440690B2 (pt) |
| KR (1) | KR102240158B1 (pt) |
| CN (1) | CN104470898B (pt) |
| AU (1) | AU2014267974B2 (pt) |
| BR (1) | BR112015027303B1 (pt) |
| CA (1) | CA2923269C (pt) |
| CY (1) | CY1120515T1 (pt) |
| DK (1) | DK2998296T3 (pt) |
| ES (1) | ES2668721T3 (pt) |
| HK (1) | HK1205118A1 (pt) |
| HU (1) | HUE037512T2 (pt) |
| LT (1) | LT2998296T (pt) |
| MX (1) | MX362747B (pt) |
| NO (1) | NO2998296T3 (pt) |
| PL (1) | PL2998296T3 (pt) |
| PT (1) | PT2998296T (pt) |
| TR (1) | TR201807104T4 (pt) |
| TW (1) | TWI654172B (pt) |
| WO (1) | WO2014183555A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3305768T1 (sl) * | 2015-05-27 | 2020-10-30 | Jiangsu Hengrui Medicine Co., Ltd., | Natrijeva sol inhibitorja transporterja sečne kisline in kristalinična oblika le-te |
| EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES |
| JP6752888B2 (ja) * | 2015-12-07 | 2020-09-09 | ヒノバ ファーマシューティカルズ インコーポレイテッド | キノリン系化合物とその調製方法および尿酸トランスポータ阻害剤類薬物としての使用 |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108201529B (zh) * | 2016-12-16 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 |
| CN111386268B (zh) * | 2017-11-23 | 2022-04-19 | 东宝紫星(杭州)生物医药有限公司 | 一种urat1抑制剂的晶型及其制备方法 |
| CN110452168B (zh) * | 2018-05-07 | 2022-03-15 | 中国医学科学院药物研究所 | N-苯基-n-喹啉羧酸类化合物及其制法和药物用途 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
| CA3117761A1 (en) * | 2018-11-02 | 2020-05-07 | Jiangsu Hengrui Medicine Co., Ltd. | Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN114315715B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与应用 |
| CN115385854B (zh) * | 2021-05-19 | 2024-04-09 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| AR051780A1 (es) | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| AR053602A1 (es) | 2005-05-03 | 2007-05-09 | Smithkline Beecham Corp | Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento |
| CA2682504C (en) | 2007-04-05 | 2012-10-30 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2008153129A1 (ja) | 2007-06-14 | 2008-12-18 | Teijin Pharma Limited | 尿酸値低下剤 |
| TWI415840B (zh) | 2007-11-27 | 2013-11-21 | Ardea Biosciences Inc | 新穎化合物、組合物及使用方法 |
| WO2010044403A1 (ja) | 2008-10-15 | 2010-04-22 | キッセイ薬品工業株式会社 | ５員環ヘテロアリール誘導体及びその医薬用途 |
| EP2488020B1 (en) | 2009-10-13 | 2016-12-14 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| CA2802692C (en) * | 2010-06-16 | 2016-01-05 | Ardea Biosciences, Inc. | Phenylthioacetate compounds useful as uricosuric agents |
-
2014
- 2014-04-29 MX MX2015015393A patent/MX362747B/es active IP Right Grant
- 2014-04-29 JP JP2016513214A patent/JP6440690B2/ja active Active
- 2014-04-29 PL PL14798044T patent/PL2998296T3/pl unknown
- 2014-04-29 CA CA2923269A patent/CA2923269C/en active Active
- 2014-04-29 NO NO14798044A patent/NO2998296T3/no unknown
- 2014-04-29 HU HUE14798044A patent/HUE037512T2/hu unknown
- 2014-04-29 ES ES14798044.5T patent/ES2668721T3/es active Active
- 2014-04-29 BR BR112015027303-3A patent/BR112015027303B1/pt active IP Right Grant
- 2014-04-29 WO PCT/CN2014/076447 patent/WO2014183555A1/zh active Application Filing
- 2014-04-29 PT PT147980445T patent/PT2998296T/pt unknown
- 2014-04-29 KR KR1020157034797A patent/KR102240158B1/ko active IP Right Grant
- 2014-04-29 US US14/889,563 patent/US9637484B2/en active Active
- 2014-04-29 CN CN201480001853.5A patent/CN104470898B/zh active Active
- 2014-04-29 LT LTEP14798044.5T patent/LT2998296T/lt unknown
- 2014-04-29 EP EP14798044.5A patent/EP2998296B1/en active Active
- 2014-04-29 TR TR2018/07104T patent/TR201807104T4/tr unknown
- 2014-04-29 DK DK14798044.5T patent/DK2998296T3/en active
- 2014-04-29 AU AU2014267974A patent/AU2014267974B2/en active Active
- 2014-05-09 TW TW103116499A patent/TWI654172B/zh active
-
2015
- 2015-06-18 HK HK15105810.0A patent/HK1205118A1/zh unknown
-
2018
- 2018-06-13 CY CY20181100621T patent/CY1120515T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO2998296T3 (pt) | 2018-08-11 |
| MX362747B (es) | 2019-02-05 |
| DK2998296T3 (en) | 2018-05-22 |
| LT2998296T (lt) | 2018-08-10 |
| KR20160006207A (ko) | 2016-01-18 |
| HUE037512T2 (hu) | 2018-08-28 |
| PL2998296T3 (pl) | 2018-12-31 |
| JP6440690B2 (ja) | 2018-12-19 |
| CN104470898A (zh) | 2015-03-25 |
| ES2668721T3 (es) | 2018-05-21 |
| US9637484B2 (en) | 2017-05-02 |
| EP2998296A4 (en) | 2016-12-14 |
| US20160108035A1 (en) | 2016-04-21 |
| PT2998296T (pt) | 2018-06-15 |
| TW201443010A (zh) | 2014-11-16 |
| TR201807104T4 (tr) | 2018-06-21 |
| KR102240158B1 (ko) | 2021-04-15 |
| EP2998296A1 (en) | 2016-03-23 |
| AU2014267974B2 (en) | 2018-08-30 |
| TWI654172B (zh) | 2019-03-21 |
| WO2014183555A1 (zh) | 2014-11-20 |
| AU2014267974A1 (en) | 2015-11-12 |
| MX2015015393A (es) | 2016-03-15 |
| JP2016520072A (ja) | 2016-07-11 |
| CY1120515T1 (el) | 2019-07-10 |
| CN104470898B (zh) | 2016-04-06 |
| BR112015027303B1 (pt) | 2023-04-25 |
| CA2923269C (en) | 2023-02-14 |
| CA2923269A1 (en) | 2014-11-20 |
| EP2998296B1 (en) | 2018-03-14 |
| HK1205118A1 (zh) | 2015-12-11 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2014, OBSERVADAS AS CONDICOES LEGAIS |